Table 3 Frequencies of drug-AE pairs and reporting rate according to the drug class by gender, and its ratio of women to men.

Drug class	Women (N = 8469)			Men (N = 7200)			Risk ratio^b (95% CI)
Drug class	Number of drug user	Drug-AE pairs	Reporting rate^a	Number of drug user	Drug-AE pairs	Reporting rate^a	Risk ratio^b (95% CI)
GLP-1RA	3167	193	609.5	2800	73	260.7	2.34 (1.79–3.05)
SGLT2 inhibitors	72,400	482	66.6	78,767	233	29.6	2.25 (1.93–2.63)
Thiazolidinedione	145,500	221	15.2	203,033	196	9.7	1.57 (1.30–1.91)
Insulin	245,800	4919	200.1	281,267	3901	138.7	1.44 (1.38–1.50)
Sulfonylurea	660,133	1096	16.6	834,033	1090	13.1	1.27 (1.17–1.38)
Metformin	1,210,667	2530	20.9	1,482,000	2445	16.5	1.27 (1.20–1.34)
DPP-4 inhibitors	812,667	1493	18.4	1,045,533	1602	15.3	1.20 (1.12–1.29)
Others	11,633	189	162.5	12,767	188	147.3	1.10 (0.90–1.35)
α-glucosidase inhibitors	54,533	146	26.8	59,733	177	29.6	0.90 (0.73–1.12)

Combination drugs were included in each drug class by corresponding ingredients.
AE adverse event, CI confidence interval, GLP-1RA glucose like peptide-1 receptor analogues, SGLT2 inhibitors sodium-glucose co-transporter 2 inhibitors, DPP4i dipeptidyl peptidase 4 inhibitors.
^aReporting rate per 10,000 people was calculated over the total number of drug users of each class.
^bReporting ratio = reporting rate of women/ reporting rate of men.

Quick links

Search